8-K: ImmunityBio Sees 467% ANKTIVA Growth, $75M Sales YTD

ImmunityBio reported significant year-to-date unit growth and sales for ANKTIVA, alongside promising clinical trial results for various cancer indications and a strengthened cash position.

Summary

• Total revenue and other income for Q3 2025 reached $33.7 million, an increase from $26.4 million in Q2 2025.
• Product revenue for Q3 2025 was $31.8 million, a 434% increase compared to $6.0 million in Q3 2024.
• Year-to-date product sales for 2025 totaled $74.7 million.
• ANKTIVA unit sales volume grew 467% year-to-date 2025 compared to fiscal year 2024.
• Cash, cash equivalents, and marketable securities stood at $257.8 million as of September 30, 2025, up from $153.7 million as of June 30, 2025.
• Net loss attributable to common stockholders decreased to $67.3 million in Q3 2025 from $85.7 million in Q3 2024.
• Early results in recurrent glioblastoma patients treated with ANKTIVA plus the Optune Gio device in combination with PD-L1 CAR-NK showed 100% disease control, including three responses and two cases of stable disease.
• Enrollment initiated in ResQ201A, a global, randomized Phase 3 study evaluating ANKTIVA in combination with TEVIMBRA and docetaxel versus docetaxel alone in patients with checkpoint inhibitor-resistant Non-Small Cell Lung Cancer (NSCLC).
• Early results from the QUILT.106 trial showed promising complete responses in the first two patients with late-stage Waldenstrom macroglobulinemia treated using CD19 CAR-NK natural killer cell therapy.
• Updated QUILT-3.032 trial data for Papillary NMIBC showed durable 36-month progression-free survival and bladder-sparing benefits of ANKTIVA plus Bacillus Calmette-Gurin (BCG).
• ImmunityBio has applied to the National Comprehensive Cancer Network (NCCN) to seek expansion of the BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) guidelines to include papillary-only disease.
• ANKTIVA was selected as the preferred drug of choice for NMIBC patients with CIS, with or without papillary tumors, by a large medication contracting organization with approximately 80 million lives under management.
• The recombinant BCG (rBCG) early access program (EAP) and its copay assistance program have been expanded.

Sentiment

Score: 8

Explanation: The filing presents very strong positive financial results, particularly in product revenue and unit growth for ANKTIVA, coupled with a significantly improved cash position and reduced net loss. Promising early clinical data across multiple oncology indications further enhances the positive outlook. While there are ongoing operational expenses and increasing liabilities, the commercial traction and clinical pipeline progress are highly favorable.

Positives

• Significant product revenue growth: 434% increase in Q3 2025 compared to Q3 2024, reaching $31.8 million.
• Strong year-to-date product sales of $74.7 million.
• Exceptional ANKTIVA unit sales volume growth of 467% year-to-date 2025 compared to fiscal year 2024.
• Improved cash position: $257.8 million as of September 30, 2025, a substantial increase from $153.7 million as of June 30, 2025.
• Reduced net loss: $67.3 million in Q3 2025, down from $85.7 million in Q3 2024, and $289.5 million year-to-date 2025, down from $354.4 million year-to-date 2024.
• Positive early clinical data for glioblastoma, showing 100% disease control in the first five patients treated with ANKTIVA combination therapy.
• Initiation of a randomized registration trial for second-line glioblastoma patients, indicating advancement towards potential approval.
• Initiation of a global, randomized Phase 3 study (ResQ201A) for checkpoint inhibitor-resistant NSCLC, expanding the clinical pipeline.
• Promising complete responses observed in early results for Non-Hodgkin Lymphoma (Waldenstrom macroglobulinemia) with CD19 CAR-NK therapy.
• Durable 36-month progression-free survival and bladder-sparing benefits for Papillary NMIBC with ANKTIVA plus BCG, demonstrating long-term efficacy.
• ANKTIVA's selection as a preferred drug by a large medication contracting organization covering ~80 million lives enhances market access and commercial traction.
• Expansion of the recombinant BCG (rBCG) early access program and copay assistance program, improving patient access and addressing the BCG shortage.

Negatives

• Research and Development (R&D) expense increased by $0.8 million to $51.2 million in Q3 2025 compared to Q3 2024, driven by higher manufacturing, distribution, and clinical trial activities.
• Selling, General and Administrative (SG&A) expense increased by $0.4 million to $36.3 million in Q3 2025 compared to Q3 2024, primarily due to higher headcount.
• Continued net loss, despite reduction, indicating ongoing operational expenses exceeding revenues.
• Related-party debt increased to $500.8 million as of September 30, 2025, from $461.9 million as of December 31, 2024.
• Revenue interest liability increased to $316.1 million as of September 30, 2025, from $284.4 million as of December 31, 2024.
• Total liabilities increased to $1,042.4 million as of September 30, 2025, from $871.1 million as of December 31, 2024.
• Total ImmunityBio stockholders deficit deepened to $(524.3) million as of September 30, 2025, from $(489.1) million as of December 31, 2024.
• Net cash used in investing activities significantly increased to $(193.4) million for the nine months ended September 30, 2025, from $(22.1) million in the prior year period.

Risks

• Risks and uncertainties regarding the FDA regulatory submission, filing, and review process and its timing, as well as for regulatory agencies outside the U.S.
• Risks and uncertainties regarding commercial launch execution, success, and timing.
• Risks and uncertainties regarding participation and enrollment and potential results from expanded access clinical investigation programs.
• Uncertainty whether clinical trials will result in registrational pathways or if clinical trial data will be accepted by regulatory agencies.
• Uncertainty regarding the NCCN's review and/or approval of the Company's submission for NMIBC guidelines expansion on the anticipated timeline or at all.
• Risks and uncertainties regarding market access initiatives and timing.
• Risks and uncertainties regarding changes in personnel at the FDA and limited resources at the FDA, potentially leading to delays.
• The ability of ImmunityBio to fund its ongoing and anticipated clinical trials.
• The ability of ImmunityBio to continue its planned preclinical and clinical development programs, including patient enrollment and planned regulatory submissions.
• Potential delays in product availability and regulatory approvals.
• Risks and uncertainties associated with third-party collaborations and agreements.
• ImmunityBio's ability to retain and hire key personnel.
• ImmunityBio's ability to obtain additional financing to fund operations and complete development and commercialization of product candidates.
• Potential product shortages or manufacturing disruptions that may impact product availability and timing.
• ImmunityBio's ability to successfully commercialize its approved product and product candidates.
• ImmunityBio's ability to scale its manufacturing and commercial supply operations.
• ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for ANKTIVA, its product candidates, and other technologies.

Future Outlook

ImmunityBio anticipates continued strong demand for ANKTIVA in NMIBC CIS and expects to expand its reach to a broader population of bladder cancer patients. The company is optimistic about the potential of its BioShield platform and ANKTIVA to address many more unmet needs in difficult-to-treat cancers like glioblastoma and non-small cell lung cancer, with ongoing clinical trials and plans for a randomized registration trial in glioblastoma.

Management Comments

• "We are pleased with the continued strong demand for ANKTIVA in NMIBC CIS. Unit sales grew nearly 6X year-to-date compared with full-year 2024, reflecting adoption both at leading research centers and in community urology clinics, including rural areas." Richard Adcock, President and CEO.
• "ANKTIVAs total response rate continues to gain momentum with payors as it was recently added as the preferred drug in its indication by a large medication contracting organization covering ~80 million lives." Richard Adcock, President and CEO.
• "Enrollment in the rBCG EAP nearly doubled this quarter, underscoring the urgent need to address the BCG shortage." Richard Adcock, President and CEO.
• "On the clinical side of the business, our BCG-nave study is enrolling well, and we are optimistic about the potential to expand ANKTIVAs reach to an even broader population of bladder cancer patients in the near future." Richard Adcock, President and CEO.
• "We continue to achieve compelling results with the core components of our BioShield platform, demonstrated by sustained demand for ANKTIVA in bladder cancer and encouraging data this quarter showing its potential to reverse lymphopenia in non-small cell lung cancer." Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer.
• "ANKTIVA also showed strong data in achieving disease control in glioblastoma, an extremely difficult to treat cancer. We are excited about the growth opportunities for our science and its potential to address many more unmet needs." Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer.

Industry Context

ImmunityBio's strong growth in ANKTIVA sales and unit volume for NMIBC positions it as a significant player in the bladder cancer treatment market, especially given the ongoing BCG shortage which ANKTIVA's early access program aims to address. The promising early clinical data in glioblastoma, NSCLC, and Non-Hodgkin Lymphoma indicates the company's broad pipeline potential in oncology, aligning with the industry trend towards multi-modal immunotherapies and cell therapies for difficult-to-treat cancers. The selection of ANKTIVA as a preferred drug by a large medication contracting organization highlights its increasing market acceptance and competitive standing in the immunotherapy space.

Related Party Transactions

• Interest expense related to related party debt was $15.3 million in Q3 2025 and $46.0 million for the nine months ended September 30, 2025.
• Related-party debt increased to $500.8 million as of September 30, 2025, from $461.9 million as of December 31, 2024.
• Research and development expenses related to related parties were $2.6 million in Q3 2025 and $7.6 million for the nine months ended September 30, 2025.
• Selling, general and administrative expenses related to related parties were $0.8 million in Q3 2025 and $1.9 million for the nine months ended September 30, 2025.
• Changes in the fair value of a related-party convertible note impacted net loss for both the three and nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced net loss, improved cash position, and promising clinical pipeline, potentially leading to increased share value.
• Patients: Enhanced access to ANKTIVA through preferred drug status and expanded early access/copay programs, offering new treatment options for various cancers.
• Employees: Higher headcount contributing to increased SG&A expenses suggests potential growth in employment opportunities.
• Payors/Healthcare Providers: ANKTIVA's selection as a preferred drug by a large medication contracting organization simplifies access and potentially reduces costs for covered lives.
• Creditors: Increased related-party debt and revenue interest liability indicate ongoing financial obligations, but improved cash flow from financing activities provides liquidity.

Next Steps

• Initiate a randomized registration trial for second-line glioblastoma patients.
• Continue enrollment in ResQ201A, a global, randomized Phase 3 study for checkpoint inhibitor-resistant NSCLC.
• Await decision from the National Comprehensive Cancer Network (NCCN) regarding the expansion of BCG-unresponsive NMIBC guidelines to include papillary-only disease.
• Continue expanding the recombinant BCG (rBCG) early access program (EAP) and copay assistance program.
• Continue enrollment in the BCG-naive study for bladder cancer patients.

Key Dates

Recommendation

The filing demonstrates exceptional commercial momentum for ANKTIVA, with significant year-over-year and year-to-date revenue and unit growth. The substantial increase in cash and reduction in net loss indicate improving financial health and operational efficiency. Furthermore, the promising early clinical data across multiple high-need oncology indications (glioblastoma, NSCLC, Non-Hodgkin Lymphoma) de-risks the pipeline and points to significant future growth potential. The expanded market access through preferred drug status and EAP programs further solidifies ANKTIVA's market position. While liabilities have increased, the overall trajectory of commercial success and clinical progress warrants a strong buy recommendation for long-term investors.

Keywords

ImmunityBio, IBRX, ANKTIVA, NMIBC, Glioblastoma, Non-Small Cell Lung Cancer, Non-Hodgkin Lymphoma, Immunotherapy, Biotechnology, Cancer Treatment, Clinical Trials, Financial Results, Product Revenue, Cash Position, FDA Approval, CAR-NK, BCG-unresponsive, Waldenstrom macroglobulinemia